Abstract
The development of atopic dermatitis (AD) in children is determined by the impact of genetic and environmental factors, epidermal barrier dysfunction, and changes in the system of innate and adaptive immunity. 76.3% of patients have IgE-mediated atopic dermatitis. The article elucidates questions of the pathogenesis and treatment of atopic dermatitis using topical corticosteroids, calcineurin inhibitors, emollients, antihistamines, allergen immunotherapy, omalizumab, probiotics. Conducting individualized pathogenetic therapy in ATD allows you to achieve control throughout the disease.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
